Is URGN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The Zusduri launch curve, with revenue (ttm) at ~$189M. The bear case rests on the company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year. Analysts covering it are spread from $48.00 to $75.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $48.00, +2.6% from the $46.80 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The Zusduri launch curve. Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second, and the underlying adoption metrics moved with it: 1,444 activated sites of care, 452 unique prescribers, and 204 repeat prescribers, or about 45% of prescribers, up from 40% a quarter earlier. The most optimistic analyst target on URGN is $75.00, +60.3% from the $46.80 price. That figure is only reachable if this thesis works close to its best case.

The company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year. About $42.4M of at-the-market equity capacity remained at June 30, 2026, so dilution is an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now the majority of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and the stock is priced for it not to. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent allowance running to 2044 has to hold up to be worth what the market is assigning it. The most pessimistic published target is $48.00, +2.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

UroGen Pharma develops and sells drugs that treat urothelial cancers without surgery, using a reverse-thermal hydrogel that holds chemotherapy against tumor tissue.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Zusduri launch curve) stalling in the reported numbers rather than in the narrative, the risk above (the company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Two approved drugs. Jelmyto treats low-grade upper tract urothelial cancer and has been on the market since 2020. Zusduri, approved in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both use UroGen's RTGel hydrogel, which turns from liquid to gel at body temperature so the chemotherapy stays in contact with tumor tissue instead of washing out.

Not yet on a net basis. The June 2026 quarter produced operating income of about $0.1M, the first positive operating figure in company history, but interest on the term loan and non-cash financing expense on the RTW obligation still left a net loss of ~$14.4M. Trailing twelve-month net loss is roughly ~$98M, down sharply from the prior year as Zusduri revenue scaled.

Zusduri. It contributed ~$50.4M in the second quarter of 2026 against nothing in the year-ago period, since FDA approval only came in June 2025. Jelmyto was ~$22.0M and slightly lower than a year earlier. Any trailing-twelve-month figure for UroGen understates the current run rate because it still contains pre-launch quarters.